Drugs / acenocoumarol
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01851824 | Aug 2013 → Jun 2014 | melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 33 trials · 2 missed | ||||||
| Phase 3 | NCT03153150 | Mar 2018 → Mar 2021 | atrial fibrillation, atrial flutter, intracerebral hemorrhage, subarachnoid hemorrhage | University of Edinburgh | Completed | Missed primary |
| Phase 3 | NCT00070655 | Sep 2003 → Mar 2006 | atrial fibrillation | Sanofi | Completed | Mixed |
| Phase 3 | NCT00062803 | Jun 2003 → Oct 2005 | pulmonary embolism | Sanofi | Completed | Missed primary |
| Phase 43 trials · 1 met primary | ||||||
| Phase 4 | NCT02826200 | Jul 2016 → Jul 2018 | cardiac valvular defect, stroke disorder | Semmelweis University Heart and Vascular Center | Unknown | No outcome recorded |
| Phase 4 | NCT01141153 | Jun 2010 → Dec 2015 | atrial fibrillation, stroke disorder | Hospital Universitari Vall d'Hebron Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT00264277 | Sep 2002 → Dec 2004 | pulmonary embolism, venous thromboembolism | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT01631877 | Jun 2012 → Jun 2017 | portal vein thrombosis | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy12 trials | ||||||
| Phase 2/3 | NCT05515120 Comparator | Jan 2021 → Jan 2022 | bleeding disorder, vascular-type, pulmonary embolism, venous thromboembolism | Mexican Social Security Institute | Completed | No outcome recorded |
| Phase 3 | NCT05825573 Comparator | May 2023 → Feb 2025 overdue | ST-elevation myocardial infarction, heart failure, thrombotic disease | Nîmes University Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02942576 Comparator | Mar 2017 → Sep 2018 | atrial fibrillation | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT02046460 Comparator | Sep 2013 → Jun 2019 | cervical artery dissection | Stefan Engelter | Completed | Missed primary |
| Phase 3 | NCT01674647 Comparator | Oct 2012 → Jan 2014 | atrial fibrillation | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01164046 Comparator | Aug 2010 → Jul 2014 | neoplasm, venous thromboembolism | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 3 | NCT00440193 Comparator | Mar 2007 → Apr 2010 | venous thromboembolism | Bayer | Completed | Met primary |
| Phase 4 | NCT04437303 Comparator | Nov 2020 → Mar 2024 | aortic valve stenosis, hemorrhagic disease, myocardial infarction, stroke disorder +2 | St. Antonius Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00711308 Comparator | Apr 2005 → Jan 2009 | pulmonary embolism | Complejo Hospitalario Xeral-Calde | Completed | No outcome recorded |
| Phase 4 | NCT00966290 Comparator | Feb 2003 → Dec 2006 | blood coagulation disease | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 4 | NCT00689520 Comparator | Jan 2002 → Jan 2005 | venous thromboembolism | Hospital Universitari de Bellvitge | Completed | No outcome recorded |
| — | NCT00512928 Background | Sep → Dec 2007 | — | Maastricht University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acenocoumarol | “subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT” PMID 21128814 ↗ Dec 201019“the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards” NCT01674647 ↗ “VKA study medications (Warfarin, Fluindione and Acenocoumarol) will be prescribed and supplied in the usual setting of patient care” NCT05825573 ↗ “For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.” NCT04437303 ↗ “treated with vitamin K antagonists (either warfarin or acenocoumarol) for a minimum of 3 months” NCT00264277 ↗ “Acenocoumarol” NCT02942576 ↗ “acenocoumarol” NCT01164046 ↗ |
| Route | Oral | “anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth” NCT00062803 ↗ |